Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,555 active trials61 approved drugs296 evidence items
- NCIt
- C156484
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,552 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,964)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01903408 | Radiotherapy of the Prostate and the Pelvic Lymph Nodes After Neoadjuvant Antihormonal Treatment(PLATIN) | completed | Phase 2 | 199 | Heidelberg UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT03058757 | The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation | completed | Phase 2 | 71 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03161132 | Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin(ROLANDO) | completed | Phase 2 | 32 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies(SIGN) | completed | Phase 2 | 116 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jan 26, 2023 | clinicaltrials |
| NCT03212651 | Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab(PANDORE) | completed | Phase 2 | 41 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT04753216 | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 3 | Northwestern UniversityOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT03617913 | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT02311049 | Hypofractionated Radiotherapy for Prostate Cancer | completed | Phase 2 | 346 | University Hospital, GhentOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT01921803 | Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer(Hypofraction) | completed | Phase 2 | 346 | University Hospital, GhentOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT02963831 | A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | completed | Phase 1 / Phase 2 | 67 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT00547339 | Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 94 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer(TOPACIO) | completed | Phase 1 / Phase 2 | 122 | Tesaro, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03464734 | Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma | completed | Phase 2 | 70 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT02680587 | Stereotactic Body Radiation for Prostate Oligometastases(ORIOLE) | completed | Phase 2 | 80 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT00805129 | Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT03980041 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | completed | Phase 2 | 49 | Infinity Pharmaceuticals, Inc.INDUSTRY | 7 | Nov 25, 2022 | clinicaltrials |
| NCT02598895 | Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway | completed | Phase 2 | 14 | University of WashingtonOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT02649439 | Prostvac in Patients With Biochemically Recurrent Prostate Cancer | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2022 | clinicaltrials |
| NCT00830895 | RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 49 | Seoul National University HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT01693783 | Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 2 | Nov 8, 2022 | clinicaltrials |
| NCT00142415 | Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer | completed | Phase 1 / Phase 2 | 26 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT01097746 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT01942837 | Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer | completed | Phase 2 | 67 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT01688999 | Cabozantinib for Advanced Urothelial Cancer | completed | Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02176161 | Metformin Prostate Cancer Adjuvant Trial | completed | Phase 2 | 59 | NYU Langone HealthOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT01717053 | Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer | completed | Phase 2 | 37 | Duke UniversityOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02431559 | Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 53 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 10, 2022 | clinicaltrials |
| NCT02440425 | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | completed | Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT02917772 | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma(TITAN-RCC) | completed | Phase 2 | 200 | AIO-Studien-gGmbHOTHER | 8 | Oct 6, 2022 | clinicaltrials |
| NCT01869413 | Tranexamic Acid During Cystectomy Trial (TACT)(TACT) | completed | Phase 2 / Phase 3 | 354 | Ottawa Hospital Research InstituteOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT02500121 | Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer | completed | Phase 2 | 108 | Matthew GalskyOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT02346526 | A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer | completed | Phase 2 | 22 | Massachusetts General HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT03470805 | Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma | completed | Phase 2 | 9 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT04685811 | Evaluation of PSMA Antagonist Produced by Two Different Methods | completed | Phase 1 / Phase 2 | 16 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT03558503 | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer(OPTIMA II) | completed | Phase 2 | 63 | UroGen Pharma Ltd.INDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT02354586 | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens(QUADRA) | completed | Phase 2 | 463 | Tesaro, Inc.INDUSTRY | 2 | Sep 15, 2022 | clinicaltrials |
| NCT02789878 | Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer | completed | Phase 2 | 64 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT03163667 | CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)(ENTRATA) | completed | Phase 2 | 69 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 15, 2022 | clinicaltrials |
| NCT02348008 | Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma: | completed | Phase 1 / Phase 2 | 61 | Arkadiusz Z. Dudek, MDOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT02089685 | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | completed | Phase 1 / Phase 2 | 295 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT02865811 | Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | completed | Phase 2 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02489695 | Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma(AXIPAP) | completed | Phase 2 | 44 | Centre Leon BerardOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT02494921 | LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC | completed | Phase 1 / Phase 2 | 43 | Rahul AggarwalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT02354131 | Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer(AVANOVA) | completed | Phase 1 / Phase 2 | 108 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 2 | Aug 30, 2022 | clinicaltrials |
| NCT04392102 | A Study of Niraparib in Patients With Relapsed Ovarian Cancer | completed | Phase 2 | 15 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Aug 29, 2022 | clinicaltrials |
| NCT03394027 | ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT02432846 | Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)(MERECA) | completed | Phase 2 | 88 | MendusINDUSTRY | 9 | Aug 22, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Feb 1, 2023source: clinicaltrials